氟18-FDG PET/CT与扩散加权MRI鉴别肺良恶性病变的Meta分析
该Meta分析比较氟18-FDG PET/CT与扩散加权MRI鉴别肺良恶性结节和肿块的诊断效能,纳入37项研究共4224例参与者、4463个病灶(恶性3090个,占69.2%)。在6项同时行两种检查的研究中,扩散加权MRI的汇总敏感度83%、特异度91%、AUC 0.93,PET/CT分别为78%、81%、AUC 0.86;作者结论为扩散加权MRI诊断效能与PET/CT相当或更优。
要点
- 扩散加权MRI鉴别肺良恶性病变的汇总AUC为0.93,PET/CT为0.86。
- 扩散加权MRI汇总敏感度83%、特异度91%,PET/CT分别为78%、81%。
- 扩散加权MRI诊断比值比50,PET/CT为15,两者差异有统计学意义。
核心结论
- 扩散加权MRI鉴别肺良恶性病变的诊断效能与氟18-FDG PET/CT相当或更优。
研究设计与样本
- 研究类型为Meta分析,检索截至2017年12月的已发表英文文献。
- 共纳入37项研究,合计4224例参与者、4463个病灶,其中恶性病灶3090个(69.2%)。
- 主要分析聚焦于全研究人群均同时行扩散加权MRI和PET/CT的6项研究,以减少研究间异质性。
- 扩散加权MRI评估病灶与脊髓信号强度比及表观扩散系数,PET/CT评估最大标准摄取值。
诊断标准与关键数值
- 同时行两种检查的6项研究中,扩散加权MRI汇总敏感度83%(95%CI:75%,89%),特异度91%(95%CI:80%,96%)。
- 同时行两种检查的6项研究中,PET/CT汇总敏感度78%(95%CI:70%,84%)(对比扩散加权MRI P=.01),特异度81%(95%CI:72%,88%)(对比扩散加权MRI P=.056)。
- 扩散加权MRI的AUC为0.93(95%CI:0.90,0.95),PET/CT为0.86(95%CI:0.83,0.89)(P=.001)。
- 扩散加权MRI诊断比值比50(95%CI:19,132),PET/CT为15(95%CI:7,32)(P=.006)。
临床应用与阅片要点
- 作者结论认为扩散加权MRI鉴别肺良恶性病变的诊断效能与氟18-FDG PET/CT相当或更优。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To perform a meta-analysis of the literature to compare the diagnostic performance of fluorine 18 fluorodeoxyglucose PET/CT and diffusion-weighted (DW) MRI in the differentiation of malignant and benign pulmonary nodules and masses. Materials and Methods Published English-language studies on the diagnostic accuracy of PET/CT and/or DW MRI in the characterization of pulmonary lesions were searched in relevant databases through December 2017. The primary focus was on studies in which joint DW MRI and PET/CT were performed in the entire study population, to reduce interstudy heterogeneity. For DW MRI, lesion-to-spinal cord signal intensity ratio and apparent diffusion coefficient were evaluated; for PET/CT, maximum standard uptake value was evaluated. The pooled sensitivities, specificities, diagnostic odds ratios, and areas under the receiver operating characteristic curve (AUCs) for PET/CT and DW MRI were determined along with 95% confidence intervals (CIs). Results Thirty-seven studies met the inclusion criteria, with a total of 4224 participants and 4463 lesions (3090 malignant lesions [69.2%]). In the primary analysis of joint DW MRI and PET/CT studies (n = 6), DW MRI had a pooled sensitivity and specificity of 83% (95% CI: 75%, 89%) and 91% (95% CI: 80%, 96%), respectively, compared with 78% (95% CI: 70%, 84%) (P = .01 vs DW MRI) and 81% (95% CI: 72%, 88%) (P = .056 vs DW MRI) for PET/CT. DW MRI yielded an AUC of 0.93 (95% CI: 0.90, 0.95), versus 0.86 (95% CI: 0.83, 0.89) for PET/CT (P = .001). The diagnostic odds ratio of DW MRI (50 [95% CI: 19, 132]) was superior to that of PET/CT (15 [95% CI: 7, 32]) (P = .006). Conclusion The diagnostic performance of diffusion-weighted MRI is comparable or superior to that of fluorine 18 fluorodeoxyglucose PET/CT in the differentiation of malignant and benign pulmonary lesions. © RSNA, 2018 Online supplemental material is available for this article. See also the editorial by Schiebler in this issue.
引用
- Basso Dias A, Zanon M, Altmayer S, et al. Fluorine 18-FDG PET/CT and Diffusion-weighted MRI for Malignant versus Benign Pulmonary Lesions: A Meta-Analysis. Radiology. 2018. PMID: 30480492. doi:10.1148/radiol.2018181159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。